Blends · Dosing reference

GLOW Blend dosage

What the human evidence does and does not show, how long studies ran, and the arithmetic for working with vials.

Not approved — research use onlyNone established

Full research page Cycle-length evidence Compare Prefer Amiravo on Google

Regulatory status: Not approved — research use only
Human amounts: None established in humans
Route studied: —
Frequency: Not established
Half-life: Not established
Evidence grade: Not yet assessed
Vial sizes on the market: 70 mg
Other forms seen: —

What GLOW Blend is

GLOW is a three-component research blend of BPC-157, TB-500, and GHK-Cu. It is the same as the KLOW blend without KPV.

No mechanism is proposed for this mixture, because no study of the mixture was identified ^5. Listing three mechanisms side by side would imply a combined mechanism that has not been demonstrated. Components, each with its own page BPC-157 ( /library/bpc-157 ) is a synthetic pentadecapeptide described as derived from a sequence found in human gastric juice, studied mainly in rodent soft-tissue injury models and not… How it works →

Key evidence

Bicer et al., Jt Dis Relat Surg · 2026 · Rats (Achilles tendon transection and repair)
BPC-157 and TB-500 given together conferred no additional effect over either peptide alone on biomechanical or histopathological endpoints; GHK-Cu was not part of the experiment. ⁷
Mendias & Awan, Sports Med · 2026 · Literature (approved and unapproved peptides including BPC-157, TB-500 and GHK-Cu)
Described these compounds as part of a gray market largely outside regulatory oversight, with favourable animal findings but scarce rigorous human safety data and potential for serious harm. ¹
Tewari et al., Am J Sports Med · 2026 · Literature (six marketed peptides including BPC-157, TB-500 and GHK-Cu)
Reported that about two-thirds of publications were animal studies, that human studies were few and mostly lacked robust controls, and that the the claimed effects remain unsubstantiated. ⁸

All studies on the research page

What the human evidence shows

No approved or established human dose

We searched PubMed and ClinicalTrials.gov and found no human studies that administered GLOW Blend. The research described on its page is from cells or animals, and animal amounts do not translate to people.

How long did human studies run?

No human study durations are recorded for GLOW Blend.

Cycle-length evidence for GLOW Blend

GLOW Blend draw calculator

Pick the vial strength and the water added, enter an amount, and see the concentration, the units to draw and how many draws the vial holds. Arithmetic only.

1 · Vial strength

sizes on the market

2 · Water added

3 · Amount per draw

4 · Syringe

Your mix

70 mg + 2 mL water = 35 mg/mL

10 units holds 3.5 mg

Draw toEnter an amount in step 3

U-100 syringe · 100 units = 1 mL

Computed from your inputs. Not a dose or a recommendation.

Compare water volumes for this vialShow

More water = lower concentration = a larger, easier-to-measure draw. Tap a row to use it.

Water	mg/mL	Draw
0.5 mL	140	—
1 mL	70	—
1.5 mL	46.67	—
2 mL	35	—
2.5 mL	28	—
3 mL	23.33	—
5 mL	14	—

Supplies and handling

Lyophilized vial
Sealed vial with the freeze-dried cake. Check the label, lot and the certificate of analysis before opening.
Sterile diluent
The diluent named on the product documentation. Bacteriostatic water contains benzyl alcohol; sterile water does not.
Graduated syringes
Sized to the volume being measured. U-100 insulin syringes are graduated in units where 100 units = 1 mL.
Alcohol prep pads
For wiping vial stoppers before each puncture.
Nitrile gloves
Clean gloves for aseptic handling.
Sharps container
Puncture-resistant container for used needles.

Step-by-step reconstitution guide Storage and transport accessories

Storage

General research-context handling only, and there is an added consideration for a multi-component vial: the three components are separate molecules with separate stability and solubility behaviour, and no published stability data for them combined in one container were identified. Defer to the supplier's own stability and handling documentation for the specific lot. No preparation or administration instructions are given on this page.

Lyophilized (unmixed) vials: typically stored cold and dry, away from light, as the documentation directs. Many are stable longer frozen.
Reconstituted vials: typically refrigerated (about 2–8 °C), protected from light and not frozen.
Bacteriostatic water contains benzyl alcohol, which inhibits bacterial growth in multi-use vials; sterile water has no preservative.

Handling mistakes and troubleshooting

Added the wrong volume of diluent: The concentration changes, not the amount of compound in the vial. Recalculate with the volume actually added and relabel the vial.
Shook the vial and it foamed: Let it settle in the refrigerator. Foam is a sign of agitation; some peptides aggregate when shaken. Note it on the label.
The solution is cloudy or has particles: Do not use it. Cloudiness can indicate incomplete dissolution, contamination or degradation. Record the lot and contact the supplier with the certificate of analysis.
The powder cake looks melted or shrunken before reconstitution: This can indicate the vial was exposed to heat or moisture. Record the lot and condition on arrival.
Liquid sprayed back when the needle was removed: Pressure built up in the vial. Withdraw a small volume of air while adding diluent to keep pressure neutral.

Regulatory status

Status: No approved product corresponds to this mixture, and none of the three named components is FDA-approved as a drug ^1,2. BPC-157 is named by WADA as a non-approved substance prohibited at all times, and thymosin-beta-4 and its derivatives including TB-500 are prohibited growth factors ^3. On FDA's May 14, 2026 503A bulk drug substances list, GHK-Cu appears in category 1 restricted to non-injectable routes, while BPC-157 and TB-500 do not appear in any category ^4.
United States (FDA): No FDA-approved application corresponds to this mixture or to any of its components, and DailyMed name searches for BPC-157 returned no drug label ^1,2. On FDA's May 14, 2026 503A bulk drug substances list, "GHK-Cu (except for injectable routes of administration)" sits in category 1, Bulk Drug Substances Under Evaluation, following a partial withdrawal and reinstatement of its nomination, with FDA stating it intends to consult the Pharmacy Compounding Advisory Committee before the end of February 2027 about possible inclusion on the 503A bulks list; BPC-157 and TB-500 do not appear in any of the three categories ^4. The category 1 entry for GHK-Cu excludes injectable routes, which is the route in which this blend is marketed ^4.
Sport (WADA): Section S0 of the WADA 2026 Prohibited List, Non-Approved Substances, names BPC-157 among its examples, introduced with "including but not limited to", and prohibits at all times any pharmacological substance with no current approval by any governmental regulatory health authority for human therapeutic use ^3. Section S2.3, Growth Factors and Growth Factor Modulators, names thymosin-beta-4 and its derivatives, with TB-500 given as an example, likewise with "including, but not limited to" wording ^3. GHK-Cu is not named in the 2026 list; given the open-ended S0 wording, that absence is hedged negative evidence rather than clearance ^3.

Status varies by country and changes over time. How we describe regulatory status.

GLOW Blend compared with related compounds

Compound	Status	Evidence	Human amounts	Half-life
GLOW Blend	Not approved — research use only	—	None established	—
KLOW Blend	Not approved — research use only	—	None established	—
BPC-157	Not approved — research use only	C	None established	—
Thymosin beta-4	Investigational	B	Trial doses	Not reported numerically in the sources
TB-500	Not approved — research use only	C	None established	—
KPV	Not approved — research use only	C	None established	—

Frequently asked questions

What doses of GLOW Blend have been studied in humans?

None that establish an amount. GLOW Blend is not approved anywhere and we found no human studies that administered it. Amiravo does not publish community or vendor figures.

Is there an established GLOW Blend cycle length?

No. We found no human studies that report treatment duration for GLOW Blend.

How much bacteriostatic water should be added to a GLOW Blend vial?

There is no compound-specific volume. The diluent volume only sets the concentration: concentration = mass in the vial ÷ volume added (for example, 10 mg in 2 mL gives 5 mg/mL). The calculator on this page shows the arithmetic for any combination.

How many units is a given amount on an insulin syringe?

On a U-100 syringe, 100 units = 1 mL. Units for an amount = amount ÷ (concentration per unit). The calculator converts any amount you enter at the concentration you choose; a unit is a volume mark, not an amount of compound.

Is GLOW Blend FDA-approved?

Not approved — research use only. No approved product corresponds to this mixture, and none of the three named components is FDA-approved as a drug ^1,2. BPC-157 is named by WADA as a non-approved substance prohibited at all times, and thymosin-beta-4 and its derivatives including TB-500 are prohibited growth factors ^3. On FDA's May 14, 2026 503A bulk drug substances list, GHK-Cu appears in category 1 restricted to non-injectable routes, while BPC-157 and TB-500 do not appear in any category ^4.

References

Last reviewed October 22, 2026 by the Amiravo editorial team. Editorial policy · Report an error